<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="676">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351763</url>
  </required_header>
  <id_info>
    <org_study_id>NCU-COVID19</org_study_id>
    <nct_id>NCT04351763</nct_id>
  </id_info>
  <brief_title>Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms</brief_title>
  <acronym>ReCOVery-SIRIO</acronym>
  <official_title>Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolaus Copernicus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicolaus Copernicus University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an urgent need for effective therapies against the novel COVID-19 virus. Studies
      have shown that amiodarone and verapamil can interfere with coronavirus entry and
      amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate
      amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with
      confirmed COVID-19 infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 27, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel group, randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Clinical events will be validated blindly by an independent clinical event committee (CEC) unaware of the treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Randomization to day 15</time_frame>
    <description>Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Randomization to day 7 and 28</time_frame>
    <description>Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the 7-point ordinal scale</measure>
    <time_frame>Randomization to day 7,15 and 28</time_frame>
    <description>assessed on a seven category scale ranging from 1 to 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Randomization to day 28</time_frame>
    <description>Individual endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Randomization to day 28</time_frame>
    <description>Defined as body temperature (≤36.6°C [axilla], or ≤37.2 °C [oral], or ≤37.8°C [rectal]) for at least 48 hours without antipyretics or until discharge, whichever is sooner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement or fever resolution</measure>
    <time_frame>Randomization to day 7,15 and 28</time_frame>
    <description>Composite endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tachyarrhythmias</measure>
    <time_frame>Randomization to day 28</time_frame>
    <description>defined as atrial fibrillation, supraventricular or ventricular tachycardia requiring treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality or tachyarrhythmias</measure>
    <time_frame>Randomization to day 28</time_frame>
    <description>Composite endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement from admission using the 7-point ordinal scale</measure>
    <time_frame>Randomization to day 28</time_frame>
    <description>Clinical improvement assessed on a seven category scale ranging from 1 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NEWS2 score</measure>
    <time_frame>Randomization to day 7 and 15</time_frame>
    <description>The National Early Warning Score (NEWS2) score. A Higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PO2/FIO2</measure>
    <time_frame>Randomization to day 7 and 15</time_frame>
    <description>oxygenation index defined as quotient of partial pressure of oxygen in arterial blood (PaO2, in mmHg) and fraction of inspired oxygen (FiO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Randomization to day 15</time_frame>
    <description>Assessed on a modified seven category scale ranging from 1 to 7</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">804</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiodarone - administered intravenously
Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.
Oral administration
200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verapamil - administered intravenously
Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.
Oral administration
120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Ion channel blocker</description>
    <arm_group_label>Amiodarone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Ion channel blocker</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Hospitalized patients with confirmed COVID-19 infection and symptoms, with an oxygenation
        index defined as quotient of partial pressure of oxygen in arterial blood (PaO2, in mmHg)
        and fraction of inspired oxygen (FiO2) &gt; 200.

        Exclusion Criteria:

          -  Acute respiratory distress syndrome (ARDS)

          -  Contraindications for or known hypersensitivity to amiodarone or calcium channel
             blockers

          -  Long QT syndrome

          -  Prolonged baseline QTc interval (≥450 ms).

          -  Cardiogenic shock or severe hypotension (SBP&lt; 90 mmHg)

          -  Severe left ventricle dysfunction (left ventricular ejection fraction ≤35%)

          -  Severe sinus - node dysfunction with marked sinus bradycardia

          -  2nd/3rd degree heart block

          -  Bradycardia without pacemaker that has caused syncope

          -  History of severe dysthyroidism

          -  A-Fib/flutter conducted via accessory pathway (ie,Wolff -Parkinson-White)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. Eliano P Navarese, MD, PhD</last_name>
    <phone>+48 885 101 728</phone>
    <email>elianonavarese@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof. Jacek Kubica, MD, PhD</last_name>
    <phone>+48 885 101 728</phone>
    <email>jkubica@cm.umk.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nicolaus Copernicus University</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Kubica, MD, PhD</last_name>
      <email>jwkubica@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nicolaus Copernicus University</investigator_affiliation>
    <investigator_full_name>Eliano Pio Navarese</investigator_full_name>
    <investigator_title>Prof Eliano P. Navarese, MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

